Applied Therapeutics, Inc.
APLT
$0.3987
$0.00040.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -95.44% | -101.98% | -103.12% | -104.47% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.44% | -101.98% | -103.12% | -104.47% | -- |
| Cost of Revenue | -9.58% | -44.45% | -42.11% | -29.87% | -3.11% |
| Gross Profit | -9.96% | 37.11% | 33.18% | 16.82% | 21.07% |
| SG&A Expenses | 171.58% | 76.80% | 22.50% | -2.90% | -24.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.55% | 25.85% | 0.88% | -8.69% | -10.15% |
| Operating Income | -61.61% | -47.65% | -17.59% | -5.75% | 22.20% |
| Income Before Tax | 11.81% | -94.08% | -119.93% | -178.41% | -45.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.81% | -94.08% | -119.93% | -178.41% | -45.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.81% | -94.08% | -119.93% | -178.41% | -45.15% |
| EBIT | -61.61% | -47.65% | -17.59% | -5.75% | 22.20% |
| EBITDA | -61.61% | -47.66% | -17.59% | -5.75% | -7.83% |
| EPS Basic | 39.79% | -11.87% | -17.49% | -1.33% | 46.15% |
| Normalized Basic EPS | 39.79% | -11.77% | -17.42% | -1.49% | 46.02% |
| EPS Diluted | 28.53% | -23.34% | -29.61% | -1.33% | 46.15% |
| Normalized Diluted EPS | 39.71% | -11.85% | -17.51% | -1.49% | 46.02% |
| Average Basic Shares Outstanding | 65.79% | 89.89% | 101.61% | 123.81% | 122.82% |
| Average Diluted Shares Outstanding | 68.31% | 92.96% | 105.24% | 123.81% | 122.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |